Registration for participation in the Martin Villar Haemostasis Awards has officially opened with remuneration amounting to a total of 40,000€ for the winning publications

Investigators are invited to submit their publications for consideration as soon as possible and only those articles received prior to April 1, 2009 will be considered The subject matter of the publications should be related to basic or clinical research in the area of hemostasis, specifically related to blood coagulation disorders. Additionally, the articles must have been published over the course of 2008 in any of the international journals listed in the "Citation Index".

The Martin Villar Haemostasis Awards were originally established in 2007 by the Victor Grifols Lucas Foundation with the aim of fostering scientific research and honoring Dr. Jose Martin Villar, a world renowned hematologist and a pioneer in the treatment of hemophilia in Spain. His rigor, determination and leadership during the difficult decade of the 1980s were fundamental to improving the safety of factor VIII concentrates.

All information about the Martin Villar Haemostasis Awards, including how to apply, is available at Grifols' Web site, www.grifols.com

About Grifols
Grifols is a Spanish holding company specializing in the pharmaceutical-hospital sector and is present in more than 90 countries. Since 2006, the company has been listed on the Spanish Continuous Market and forms part of the Ibex-35. Currently it is the first company in the European sector in plasma derivatives and the fourth in production worldwide. Grifols has invested heavily in its plasma procurement infrastructure and manufacturing facilities resulting in a vertically integrated company and strengthened its leadership in the industry. These recent investments combined with the ongoing investment plan to be completed in 2012 and totaling 400 million euros will ensure Grifols ability to meet the growing demand for its life saving therapies for the next 10 years.